ストックスクリーナーアプリを入手
13.75
0.07%
-0.010
前日終値:
$13.76
開ける：
$13.75
24時間の取引高:
2.56M
Relative Volume:
1.07
時価総額：
$3.61B
収益：
$6.16B
当期純損益:
$246.00M
株価収益率:
14.65
EPS:
0.9387
ネットキャッシュフロー:
$708.00M
1週間 パフォーマンス:
-0.07%
1か月 パフォーマンス:
+0.36%
6か月 パフォーマンス:
+50.44%
1年 パフォーマンス:
+53.80%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$13.71
$13.80
52週間の値動き範囲:
$5.69
$13.83
Organon Co Stock (OGN) Company Profile
Compare OGN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
13.75 | 3.61B | 6.16B | 246.00M | 708.00M | 0.9387 |
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-28 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-10-27 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal - The Economic Times
Organon & Co Says It Does Not Expect To Record Milestone Expense In Q3 2026 - TradingView
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon reports six‑year MIUDELLA data as FDA reviews longer use - Mugglehead Investment Magazine
Organon & CoFDA Accepts Snda for Miudella - Moomoo
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Zacks Investment Research
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
USU6836GAB42 Bond Yield and Price — BONDSCOM:USU6836GAB42 - TradingView
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Organon & Co stock hits 52-week high at 13.79 USD - Investing.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon presents VTAMA analysis: Organon stock gains 1.16 percent - AD HOC NEWS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Tangible book value per share of Organon & Co. – HAN:7XP - TradingView
Organon & Co. Revenue Breakdown – HAN:7XP - TradingView
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - ETPharma.com
Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan - Firstpost
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - Dealroom
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Organon Says Application to Extend Miudella IUD Use to Six Years Accepted by FDA for Review - Yahoo Finance
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon Stock: A Merger-Arbitrage Hold With Limited Upside (NYSE:OGN) - Seeking Alpha
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - pharma.economictimes.indiatimes.com
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
Organon Co (OGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Head of Mfg & Supply |
Aug 05 '26 |
Sale |
13.57 |
14,761 |
200,307 |
18,475 |
| JULIANA P DRINANE | Officer |
Aug 05 '26 |
Proposed Sale |
13.57 |
14,761 |
200,307 |
0 |
| Holzbaur Lynette | SVP and Corporate Controller |
May 06 '26 |
Buy |
13.35 |
26,448 |
353,080 |
52,851 |
| Holzbaur Lynette | Affiliate |
May 06 '26 |
Proposed Sale |
13.35 |
26,448 |
353,080 |
0 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '26 |
Option Exercise |
0.00 |
17,925 |
0 |
105,265 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '26 |
Option Exercise |
0.00 |
18,513 |
0 |
96,147 |
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '26 |
Option Exercise |
0.00 |
13,000 |
0 |
73,494 |
| Holzbaur Lynette | SVP and Corporate Controller |
Mar 31 '26 |
Option Exercise |
0.00 |
10,967 |
0 |
28,316 |
| Morrissey Joseph T. Jr. | Interim CEO |
Mar 31 '26 |
Option Exercise |
0.00 |
24,584 |
0 |
127,907 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '26 |
Option Exercise |
0.00 |
13,431 |
0 |
34,867 |
0.53%
0.26%
大文字化:
|
ボリューム (24 時間):